Medicare Approved Facilities/Trials/Registries PET for Dementia Trials
Guidance for Medicare Approved Facilities/Trials/Registries on the National Coverage Determination for PET (FDG) for Dementia and Neurodegenerative Diseases.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: May 21, 2012
Additionally, in a National Coverage Determination for PET (FDG) for Dementia and Neurodegenerative Diseases (220.6.13) the Centers for Medicare & Medicaid Services (CMS) indicated that an FDG-PET scan is considered reasonable and necessary in patients with mild cognitive impairment or early dementia only in the context of an approved clinical trial that contains patient safeguards and protections to ensure proper administration, use and evaluation of the FDG-PET scan.
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.